✦ LIBER ✦

Fondaparinux dominates enoxaparin sodium for non-ST-segment elevation acute coronary syndromes in French hospital setting

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV67 COST-EFFECTIVENESS OF FONDAPARINUX

✍ PA Vorobyev; O Borisenko; M Lesnicheva; S Shiganov; A Lomakin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Enoxaparin versus tinzaparin in non-ST–s

✍ Lampros K Michalis; Christos S Katsouras; Nikos Papamichael; Kostas Adamides; Ka 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 104 KB

PCV47 COST-EFFECTIVENESS OF FONDAPARINUX

✍ C. Pepe; M. Machado; A. Olimpio; M. Canella; R. Ramos 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Impact of fondaparinux versus enoxaparin

✍ Puymirat, E.; Schiele, F.; Ennezat, P.-V.; Coste, P.; Collet, J.-P.; Bonnefoy-Cu 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 836 KB

At six months, enoxaparin is more effect

✍ Marc Cohen; Debbie Singh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Enoxaparin versus tinzaparin in non–ST-s

✍ Christos Katsouras; Lampros K. Michalis; Nikos Papamichael; Kostas Adamides; Kat 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 237 KB